{"product_id":"injectable-s23-400mg-vial","title":"Injectable RAD140 500mg vial","description":"\u003cp\u003e\u003cspan\u003e\u003cstrong\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"576\" data-start=\"53\"\u003e\u003cstrong\u003eRAD-140 \u003c\/strong\u003e(testolone) is an oral, non-steroidal \u003cstrong data-end=\"180\" data-start=\"132\"\u003eselective androgen receptor modulator (SARM)\u003c\/strong\u003e engineered to deliver \u003cstrong data-end=\"242\" data-start=\"203\"\u003eanabolic effects in muscle and bone\u003c\/strong\u003e with comparatively \u003cstrong data-end=\"299\" data-start=\"262\"\u003eless stimulation of prostate\/skin\u003c\/strong\u003e than testosterone. It binds the \u003cstrong data-end=\"358\" data-start=\"332\"\u003eandrogen receptor (AR)\u003c\/strong\u003e, recruits muscle\/bone-biased co-activators, and—unlike testosterone—\u003cstrong data-end=\"462\" data-start=\"427\"\u003edoes not aromatize to estradiol\u003c\/strong\u003e or undergo 5-α reduction. RAD-140 is \u003cstrong data-end=\"524\" data-start=\"500\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e and is \u003cstrong data-end=\"554\" data-start=\"532\"\u003eprohibited by WADA\u003c\/strong\u003e as an anabolic agent.\u003c\/p\u003e\n\u003chr data-end=\"581\" data-start=\"578\"\u003e\n\u003ch3 data-end=\"641\" data-start=\"583\"\u003eAdditional Benefits of RAD-140 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2900\" data-start=\"643\"\u003e\n\u003cthead data-end=\"671\" data-start=\"643\"\u003e\n\u003ctr data-end=\"671\" data-start=\"643\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"653\" data-start=\"643\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"671\" data-start=\"653\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2900\" data-start=\"682\"\u003e\n\u003ctr data-end=\"1026\" data-start=\"682\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"751\" data-start=\"682\"\u003e\u003cstrong data-end=\"750\" data-start=\"684\"\u003e1 Potent lean-mass accrual (preclinical → early translational)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1026\" data-start=\"751\"\u003eIn castrate\/ovariectomy and diet-induced models, RAD-140 \u003cstrong data-end=\"854\" data-start=\"810\"\u003eincreases fat-free mass and myofiber CSA\u003c\/strong\u003e with \u003cstrong data-end=\"892\" data-start=\"860\"\u003elimited prostate stimulation\u003c\/strong\u003e—per-mg potency among the higher in the SARM class. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Pharmacology \u0026amp; Experimental Therapeutics; FASEB Journal\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1274\" data-start=\"1027\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1055\" data-start=\"1027\"\u003e\u003cstrong data-end=\"1054\" data-start=\"1029\"\u003e2 Strength \u0026amp; function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1274\" data-start=\"1055\" data-col-size=\"xl\"\u003eImproves \u003cstrong data-end=\"1133\" data-start=\"1066\"\u003especific force, grip strength, and stair\/peak torque surrogates\u003c\/strong\u003e in animal\/bench models; human functional datasets remain limited. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Medicine \u0026amp; Science in Sports \u0026amp; Exercise; AJP–Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1489\" data-start=\"1275\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1305\" data-start=\"1275\"\u003e\u003cstrong data-end=\"1304\" data-start=\"1277\"\u003e3 Bone-anabolic effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1489\" data-start=\"1305\" data-col-size=\"xl\"\u003eRaises \u003cstrong data-end=\"1321\" data-start=\"1314\"\u003eBMD\u003c\/strong\u003e, enhances \u003cstrong data-end=\"1359\" data-start=\"1332\"\u003etrabecular architecture\u003c\/strong\u003e, and improves \u003cstrong data-end=\"1400\" data-start=\"1374\"\u003ebiomechanical strength\u003c\/strong\u003e with modest prostate changes. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Bone and Mineral Research; Bone\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1712\" data-start=\"1490\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1526\" data-start=\"1490\"\u003e\u003cstrong data-end=\"1525\" data-start=\"1492\"\u003e4 Anti-catabolic under stress\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1712\" data-start=\"1526\" data-col-size=\"xl\"\u003e\n\u003cstrong data-end=\"1567\" data-start=\"1528\"\u003eDown-shifts atrogenes (MAFbx\/MuRF1)\u003c\/strong\u003e and preserves CSA during \u003cstrong data-end=\"1632\" data-start=\"1593\"\u003eglucocorticoids, disuse, or illness\u003c\/strong\u003e in preclinical studies. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Endocrine Reviews; Molecular Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1937\" data-start=\"1713\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1755\" data-start=\"1713\"\u003e\u003cstrong data-end=\"1754\" data-start=\"1715\"\u003e5 Body-composition “repartitioning”\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1937\" data-start=\"1755\"\u003eIn obese models, \u003cstrong data-end=\"1794\" data-start=\"1774\"\u003ereduces fat mass\u003c\/strong\u003e while preserving or increasing lean tissue—largely via AR-mTOR activation and improved oxidative programs. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Obesity; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2204\" data-start=\"1938\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1970\" data-start=\"1938\"\u003e\u003cstrong data-end=\"1969\" data-start=\"1940\"\u003e6 Neuroprotection signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2204\" data-start=\"1970\"\u003eAR agonism with RAD-class ligands \u003cstrong data-end=\"2038\" data-start=\"2006\"\u003eprotects hippocampal neurons\u003c\/strong\u003e, enhances synaptic markers, and improves memory tasks in injury\/aging models (translational relevance pending). \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Neurobiology of Aging; Brain Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2449\" data-start=\"2205\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2253\" data-start=\"2205\"\u003e\u003cstrong data-end=\"2252\" data-start=\"2207\"\u003e7 AR-positive breast cancer (preclinical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2449\" data-start=\"2253\"\u003eIn ER⁺\/AR⁺ models, selective AR agonism \u003cstrong data-end=\"2321\" data-start=\"2295\"\u003einhibits proliferation\u003c\/strong\u003e and shows \u003cstrong data-end=\"2369\" data-start=\"2332\"\u003eadditivity with CDK4\/6 inhibitors\u003c\/strong\u003e—clinical validation needed. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cancer Research; Annals of Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2662\" data-start=\"2450\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2472\" data-start=\"2450\"\u003e\u003cstrong data-end=\"2471\" data-start=\"2452\"\u003e8 Rehab synergy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2662\" data-start=\"2472\"\u003ePairing with \u003cstrong data-end=\"2522\" data-start=\"2487\"\u003eprogressive resistance training\u003c\/strong\u003e yields \u003cstrong data-end=\"2542\" data-start=\"2530\"\u003eadditive\u003c\/strong\u003e hypertrophy\/function vs either alone in translational paradigms. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sports Medicine; Journal of Physiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2900\" data-start=\"2663\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2688\" data-start=\"2663\"\u003e\u003cstrong data-end=\"2687\" data-start=\"2665\"\u003e9 Oral convenience\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2900\" data-start=\"2688\"\u003e\n\u003cstrong data-end=\"2709\" data-start=\"2690\"\u003eOnce-daily oral\u003c\/strong\u003e administration with long detection metabolites supports adherence in trials—also increases anti-doping scrutiny. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Pharmacology \u0026amp; Therapeutics; Drug Testing \u0026amp; Analysis\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2905\" data-start=\"2902\"\u003e\n\u003ch2 data-end=\"2942\" data-start=\"2907\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2979\" data-start=\"2944\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3370\" data-start=\"2980\"\u003eRAD-140 binds \u003cstrong data-end=\"3000\" data-start=\"2994\"\u003eAR\u003c\/strong\u003e → nuclear translocation → \u003cstrong data-end=\"3055\" data-start=\"3027\"\u003eARE-driven transcription\u003c\/strong\u003e. In muscle it \u003cstrong data-end=\"3102\" data-start=\"3070\"\u003eup-regulates mTOR\/S6K\/4E-BP1\u003c\/strong\u003e and local \u003cstrong data-end=\"3122\" data-start=\"3113\"\u003eIGF-1\u003c\/strong\u003e, while \u003cstrong data-end=\"3160\" data-start=\"3130\"\u003esuppressing FoxO-atrogenes\u003c\/strong\u003e; in bone, AR signaling promotes \u003cstrong data-end=\"3215\" data-start=\"3193\"\u003eosteoblastogenesis\u003c\/strong\u003e (Wnt\/β-catenin\/Osterix) and may indirectly restrain resorption. Lack of aromatization\/5-α reduction contributes to \u003cstrong data-end=\"3353\" data-start=\"3331\"\u003etissue selectivity\u003c\/strong\u003e vs testosterone.\u003c\/p\u003e\n\u003ch3 data-end=\"3399\" data-start=\"3372\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3868\" data-start=\"3401\"\u003e\n\u003cthead data-end=\"3443\" data-start=\"3401\"\u003e\n\u003ctr data-end=\"3443\" data-start=\"3401\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3411\" data-start=\"3401\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3432\" data-start=\"3411\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3443\" data-start=\"3432\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3868\" data-start=\"3458\"\u003e\n\u003ctr data-end=\"3548\" data-start=\"3458\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3485\" data-start=\"3458\"\u003e\u003cstrong data-end=\"3484\" data-start=\"3460\"\u003eAR → mTOR\/S6K\/4E-BP1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3529\" data-start=\"3485\"\u003e↑ protein synthesis, myofiber hypertrophy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3548\" data-start=\"3529\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3621\" data-start=\"3549\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3582\" data-start=\"3549\"\u003e\u003cstrong data-end=\"3581\" data-start=\"3551\"\u003eAR ↔ Wnt\/β-catenin\/Osterix\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3613\" data-start=\"3582\"\u003e↑ osteoblast activity, ↑ BMD\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3621\" data-start=\"3613\"\u003eBone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3701\" data-start=\"3622\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3648\" data-start=\"3622\"\u003e\u003cstrong data-end=\"3647\" data-start=\"3624\"\u003eFoxO → MAFbx\/MuRF1↓\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3681\" data-start=\"3648\"\u003e↓ proteolysis (anti-catabolic)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3701\" data-start=\"3681\"\u003eCatabolic stress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3766\" data-start=\"3702\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3736\" data-start=\"3702\"\u003e\u003cstrong data-end=\"3735\" data-start=\"3704\"\u003eMyostatin\/activin crosstalk\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3756\" data-start=\"3736\"\u003eNet anabolic bias\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3766\" data-start=\"3756\"\u003eMuscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3868\" data-start=\"3767\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3811\" data-start=\"3767\"\u003e\u003cstrong data-end=\"3810\" data-start=\"3769\"\u003eNeurotrophic signaling (AR-dependent)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3861\" data-start=\"3811\"\u003eSynaptic support, neuroprotection (preclinical)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3868\" data-start=\"3861\"\u003eCNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3873\" data-start=\"3870\"\u003e\n\u003ch2 data-end=\"3897\" data-start=\"3875\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4332\" data-start=\"3899\"\u003e\n\u003cli data-end=\"3919\" data-start=\"3899\"\u003e\n\u003cp data-end=\"3919\" data-start=\"3901\"\u003e\u003cstrong data-end=\"3911\" data-start=\"3901\"\u003eRoute:\u003c\/strong\u003e Oral.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4141\" data-start=\"3920\"\u003e\n\u003cp data-end=\"4141\" data-start=\"3922\"\u003e\u003cstrong data-end=\"3945\" data-start=\"3922\"\u003eExposure\/half-life:\u003c\/strong\u003e \u003cstrong data-end=\"3990\" data-start=\"3946\"\u003eHuman PK has not been formally published\u003c\/strong\u003e; industry\/forensic reports suggest a \u003cstrong data-end=\"4089\" data-start=\"4028\"\u003elong terminal half-life compatible with once-daily dosing\u003c\/strong\u003e and \u003cstrong data-end=\"4129\" data-start=\"4094\"\u003emulti-week metabolite detection\u003c\/strong\u003e in urine.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4233\" data-start=\"4142\"\u003e\n\u003cp data-end=\"4233\" data-start=\"4144\"\u003e\u003cstrong data-end=\"4159\" data-start=\"4144\"\u003eMetabolism:\u003c\/strong\u003e Hepatic oxidative\/conjugative clearance; \u003cstrong data-end=\"4221\" data-start=\"4201\"\u003eno aromatase\/5-α\u003c\/strong\u003e pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4280\" data-start=\"4234\"\u003e\n\u003cp data-end=\"4280\" data-start=\"4236\"\u003e\u003cstrong data-end=\"4256\" data-start=\"4236\"\u003eProtein binding:\u003c\/strong\u003e High (class feature).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4332\" data-start=\"4281\"\u003e\n\u003cp data-end=\"4332\" data-start=\"4283\"\u003e\u003cstrong data-end=\"4299\" data-start=\"4283\"\u003eFood effect:\u003c\/strong\u003e Not well characterized publicly.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4337\" data-start=\"4334\"\u003e\n\u003ch2 data-end=\"4384\" data-start=\"4339\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4413\" data-start=\"4386\"\u003e4.1 Muscle \u0026amp; Function\u003c\/h3\u003e\n\u003cp data-end=\"4562\" data-start=\"4414\"\u003eRobust \u003cstrong data-end=\"4444\" data-start=\"4421\"\u003elean-mass and force\u003c\/strong\u003e improvements in rodent models, with \u003cstrong data-end=\"4511\" data-start=\"4481\"\u003elower prostate stimulation\u003c\/strong\u003e than testosterone for comparable anabolic effects.\u003c\/p\u003e\n\u003ch3 data-end=\"4578\" data-start=\"4564\"\u003e4.2 Bone\u003c\/h3\u003e\n\u003cp data-end=\"4734\" data-start=\"4579\"\u003eIn ovariectomized models, \u003cstrong data-end=\"4624\" data-start=\"4605\"\u003espine\/femur BMD\u003c\/strong\u003e and \u003cstrong data-end=\"4658\" data-start=\"4629\"\u003ethree-point-bend strength\u003c\/strong\u003e improve, supporting exploration as an \u003cstrong data-end=\"4719\" data-start=\"4697\"\u003eosteopenia adjunct\u003c\/strong\u003e (preclinical).\u003c\/p\u003e\n\u003ch3 data-end=\"4755\" data-start=\"4736\"\u003e4.3 Neuro\/CNS\u003c\/h3\u003e\n\u003cp data-end=\"4920\" data-start=\"4756\"\u003eAndrogen-axis agonism with RAD-class ligands shows \u003cstrong data-end=\"4828\" data-start=\"4807\"\u003eneuronal survival\u003c\/strong\u003e and \u003cstrong data-end=\"4856\" data-start=\"4833\"\u003esynaptic plasticity\u003c\/strong\u003e benefits in injury\/aging models; human translation is untested.\u003c\/p\u003e\n\u003ch3 data-end=\"4957\" data-start=\"4922\"\u003e4.4 Oncology (AR⁺\/ER⁺ breast)\u003c\/h3\u003e\n\u003cp data-end=\"5111\" data-start=\"4958\"\u003eSelective AR activation via non-steroidal ligands can \u003cstrong data-end=\"5047\" data-start=\"5012\"\u003einhibit ER-driven proliferation\u003c\/strong\u003e in preclinical systems; RAD-140 is part of this research space.\u003c\/p\u003e\n\u003cblockquote data-end=\"5325\" data-start=\"5113\"\u003e\n\u003cp data-end=\"5325\" data-start=\"5115\"\u003e\u003cstrong data-end=\"5141\" data-start=\"5115\"\u003eEvidence quality note:\u003c\/strong\u003e For RAD-140 specifically, \u003cstrong data-end=\"5209\" data-start=\"5168\"\u003ehuman efficacy\/safety data are sparse\u003c\/strong\u003e. Most signals derive from \u003cstrong data-end=\"5255\" data-start=\"5236\"\u003eanimal\/in-vitro\u003c\/strong\u003e work and \u003cstrong data-end=\"5290\" data-start=\"5265\"\u003eanti-doping forensics\u003c\/strong\u003e rather than registrational trials.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5330\" data-start=\"5327\"\u003e\n\u003ch2 data-end=\"5365\" data-start=\"5332\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5908\" data-start=\"5367\"\u003e\n\u003cthead data-end=\"5405\" data-start=\"5367\"\u003e\n\u003ctr data-end=\"5405\" data-start=\"5367\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5375\" data-start=\"5367\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5387\" data-start=\"5375\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5405\" data-start=\"5387\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5908\" data-start=\"5420\"\u003e\n\u003ctr data-end=\"5525\" data-start=\"5420\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5445\" data-start=\"5420\"\u003e\u003cstrong data-end=\"5444\" data-start=\"5422\"\u003eSarcopenia\/frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5490\" data-start=\"5445\"\u003eOral anabolic with prostate-sparing intent\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5525\" data-start=\"5490\"\u003ePreclinical\/early translational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5614\" data-start=\"5526\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5562\" data-start=\"5526\"\u003e\u003cstrong data-end=\"5561\" data-start=\"5528\"\u003eRehabilitation\/immobilization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5596\" data-start=\"5562\"\u003ePreserve\/restore FFM \u0026amp; function\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5614\" data-start=\"5596\"\u003eConcept pilots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5712\" data-start=\"5615\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5655\" data-start=\"5615\"\u003e\u003cstrong data-end=\"5654\" data-start=\"5617\"\u003eOsteopenia\/osteoporosis (adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5697\" data-start=\"5655\"\u003eBone-anabolic + anti-resorptive balance\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5712\" data-start=\"5697\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5792\" data-start=\"5713\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5728\" data-start=\"5713\"\u003e\u003cstrong data-end=\"5727\" data-start=\"5715\"\u003eCachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5777\" data-start=\"5728\"\u003eAppetite-neutral anabolism vs ghrelin mimetics\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5792\" data-start=\"5777\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5908\" data-start=\"5793\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5821\" data-start=\"5793\"\u003e\u003cstrong data-end=\"5820\" data-start=\"5795\"\u003eAR⁺\/ER⁺ breast cancer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5866\" data-start=\"5821\"\u003eSelective AR agonism as antitumor strategy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5908\" data-start=\"5866\"\u003ePreclinical\/early clinical exploration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5913\" data-start=\"5910\"\u003e\n\u003ch2 data-end=\"5944\" data-start=\"5915\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6875\" data-start=\"5946\"\u003e\n\u003cli data-end=\"6087\" data-start=\"5946\"\u003e\n\u003cp data-end=\"6087\" data-start=\"5948\"\u003e\u003cstrong data-end=\"5962\" data-start=\"5948\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-end=\"6002\" data-start=\"5963\"\u003eDose-dependent HPG-axis suppression\u003c\/strong\u003e (↓ LH\/FSH\/testosterone) expected; recovery often \u003cstrong data-end=\"6068\" data-start=\"6052\"\u003eweeks–months\u003c\/strong\u003e after cessation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6173\" data-start=\"6088\"\u003e\n\u003cp data-end=\"6173\" data-start=\"6090\"\u003e\u003cstrong data-end=\"6101\" data-start=\"6090\"\u003eLipids:\u003c\/strong\u003e \u003cstrong data-end=\"6121\" data-start=\"6102\"\u003eHDL-C reduction\u003c\/strong\u003e (± ↑ LDL\/TG) common across SARMs—monitor CV risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6371\" data-start=\"6174\"\u003e\n\u003cp data-end=\"6371\" data-start=\"6176\"\u003e\u003cstrong data-end=\"6188\" data-start=\"6176\"\u003eHepatic:\u003c\/strong\u003e Short controlled datasets are limited; \u003cstrong data-end=\"6285\" data-start=\"6228\"\u003ecase reports of cholestatic\/drug-induced liver injury\u003c\/strong\u003e exist with unregulated RAD-140–containing products (purity\/co-ingestants confound).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6454\" data-start=\"6372\"\u003e\n\u003cp data-end=\"6454\" data-start=\"6374\"\u003e\u003cstrong data-end=\"6381\" data-start=\"6374\"\u003eCV:\u003c\/strong\u003e No outcome data; lipid shifts and possible BP effects warrant caution.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6553\" data-start=\"6455\"\u003e\n\u003cp data-end=\"6553\" data-start=\"6457\"\u003e\u003cstrong data-end=\"6485\" data-start=\"6457\"\u003eDermatologic\/androgenic:\u003c\/strong\u003e \u003cstrong data-end=\"6504\" data-start=\"6486\"\u003eAcne\/oily skin\u003c\/strong\u003e, \u003cstrong data-end=\"6523\" data-start=\"6506\"\u003ehair shedding\u003c\/strong\u003e in predisposed individuals.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6658\" data-start=\"6554\"\u003e\n\u003cp data-end=\"6658\" data-start=\"6556\"\u003e\u003cstrong data-end=\"6571\" data-start=\"6556\"\u003eNeuropsych:\u003c\/strong\u003e \u003cstrong data-end=\"6607\" data-start=\"6572\"\u003eInsomnia, irritability, anxiety\u003c\/strong\u003e occasionally described in uncontrolled settings.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6742\" data-start=\"6659\"\u003e\n\u003cp data-end=\"6742\" data-start=\"6661\"\u003e\u003cstrong data-end=\"6677\" data-start=\"6661\"\u003eHematologic:\u003c\/strong\u003e \u003cstrong data-end=\"6699\" data-start=\"6678\"\u003eMild ↑ hematocrit\u003c\/strong\u003e possible—monitor in at-risk populations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6875\" data-start=\"6743\"\u003e\n\u003cp data-end=\"6875\" data-start=\"6745\"\u003e\u003cstrong data-end=\"6767\" data-start=\"6745\"\u003eDrug interactions:\u003c\/strong\u003e Potential with drugs affecting \u003cstrong data-end=\"6825\" data-start=\"6799\"\u003ehepatic enzymes\/lipids\u003c\/strong\u003e; avoid \u003cstrong data-end=\"6849\" data-start=\"6833\"\u003ehepatotoxins\u003c\/strong\u003e and \u003cstrong data-end=\"6874\" data-start=\"6854\"\u003euse in pregnancy\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6906\" data-start=\"6877\"\u003e\u003cstrong data-end=\"6906\" data-start=\"6877\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7415\" data-start=\"6908\"\u003e\n\u003cthead data-end=\"6974\" data-start=\"6908\"\u003e\n\u003ctr data-end=\"6974\" data-start=\"6908\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6918\" data-start=\"6908\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6932\" data-start=\"6918\"\u003e\u003cstrong data-end=\"6931\" data-start=\"6920\"\u003eRAD-140\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6947\" data-start=\"6932\"\u003e\u003cstrong data-end=\"6946\" data-start=\"6934\"\u003eLGD-4033\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6974\" data-start=\"6947\"\u003e\u003cstrong data-end=\"6972\" data-start=\"6949\"\u003eEnobosarm (MK-2866)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7415\" data-start=\"6993\"\u003e\n\u003ctr data-end=\"7068\" data-start=\"6993\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7010\" data-start=\"6993\"\u003eHuman evidence\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7029\" data-start=\"7010\"\u003e\u003cstrong data-end=\"7028\" data-start=\"7012\"\u003eVery limited\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7048\" data-start=\"7029\"\u003eSmall RCT (21 d)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7068\" data-start=\"7048\"\u003eMultiple Phase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7132\" data-start=\"7069\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7087\" data-start=\"7069\"\u003eHPG suppression\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7109\" data-start=\"7087\"\u003e\u003cstrong data-end=\"7108\" data-start=\"7089\"\u003eModerate–strong\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7120\" data-start=\"7109\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7132\" data-start=\"7120\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7184\" data-start=\"7133\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7146\" data-start=\"7133\"\u003eHDL impact\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7161\" data-start=\"7146\"\u003e\u003cstrong data-end=\"7160\" data-start=\"7148\"\u003e↓ Common\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7172\" data-start=\"7161\"\u003e↓ Common\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7184\" data-start=\"7172\"\u003e↓ Common\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7245\" data-start=\"7185\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7208\" data-start=\"7185\"\u003eProstate stimulation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7232\" data-start=\"7208\"\u003e\n\u003cstrong data-end=\"7217\" data-start=\"7210\"\u003eLow\u003c\/strong\u003e (preclinical)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7238\" data-start=\"7232\"\u003eLow\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7245\" data-start=\"7238\"\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7342\" data-start=\"7246\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7270\" data-start=\"7246\"\u003eHepatotoxicity signal\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7303\" data-start=\"7270\"\u003e\u003cstrong data-end=\"7302\" data-start=\"7272\"\u003eCase reports (unregulated)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7318\" data-start=\"7303\"\u003eCase reports\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7342\" data-start=\"7318\"\u003eCase reports (rarer)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7415\" data-start=\"7343\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7356\" data-start=\"7343\"\u003eRoute \/ t½\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7384\" data-start=\"7356\"\u003eOral; \u003cstrong data-end=\"7372\" data-start=\"7364\"\u003elong\u003c\/strong\u003e (inferred)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7400\" data-start=\"7384\"\u003eOral; 24–36 h\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7415\" data-start=\"7400\"\u003eOral; ~24 h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7420\" data-start=\"7417\"\u003e\n\u003ch2 data-end=\"7448\" data-start=\"7422\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7784\" data-start=\"7450\"\u003e\n\u003cli data-end=\"7505\" data-start=\"7450\"\u003e\n\u003cp data-end=\"7505\" data-start=\"7452\"\u003e\u003cstrong data-end=\"7466\" data-start=\"7452\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-end=\"7475\" data-start=\"7467\"\u003eNone\u003c\/strong\u003e for any medical indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7653\" data-start=\"7506\"\u003e\n\u003cp data-end=\"7653\" data-start=\"7508\"\u003e\u003cstrong data-end=\"7518\" data-start=\"7508\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"7538\" data-start=\"7519\"\u003eWADA-prohibited\u003c\/strong\u003e (S1, Other Anabolic Agents) at all times; detection of \u003cstrong data-end=\"7619\" data-start=\"7594\"\u003elong-term metabolites\u003c\/strong\u003e enables \u003cstrong data-end=\"7642\" data-start=\"7628\"\u003eweeks-long\u003c\/strong\u003e windows.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7784\" data-start=\"7654\"\u003e\n\u003cp data-end=\"7784\" data-start=\"7656\"\u003e\u003cstrong data-end=\"7675\" data-start=\"7656\"\u003eMarket quality:\u003c\/strong\u003e Grey-market products frequently show \u003cstrong data-end=\"7741\" data-start=\"7713\"\u003eadulteration\/mislabeling\u003c\/strong\u003e; medical use outside trials is \u003cstrong data-end=\"7783\" data-start=\"7773\"\u003eunsafe\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7789\" data-start=\"7786\"\u003e\n\u003ch2 data-end=\"7814\" data-start=\"7791\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8553\" data-start=\"7816\"\u003e\n\u003cli data-end=\"7923\" data-start=\"7816\"\u003e\n\u003cp data-end=\"7923\" data-start=\"7818\"\u003e\u003cstrong data-end=\"7842\" data-start=\"7818\"\u003eFirst-in-human PK\/PD\u003c\/strong\u003e with \u003cstrong data-end=\"7855\" data-start=\"7848\"\u003eGMP\u003c\/strong\u003e material to define \u003cstrong data-end=\"7920\" data-start=\"7875\"\u003ehalf-life, metabolites, exposure–response\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8041\" data-start=\"7924\"\u003e\n\u003cp data-end=\"8041\" data-start=\"7926\"\u003e\u003cstrong data-end=\"7942\" data-start=\"7926\"\u003eHead-to-head\u003c\/strong\u003e vs other SARMs for \u003cstrong data-end=\"7991\" data-start=\"7962\"\u003eanabolic:androgenic ratio\u003c\/strong\u003e, \u003cstrong data-end=\"8013\" data-start=\"7993\"\u003elipid neutrality\u003c\/strong\u003e, and \u003cstrong data-end=\"8038\" data-start=\"8019\"\u003eHPG suppression\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8150\" data-start=\"8042\"\u003e\n\u003cp data-end=\"8150\" data-start=\"8044\"\u003e\u003cstrong data-end=\"8064\" data-start=\"8044\"\u003eLong-term safety\u003c\/strong\u003e: lipids\/CV outcomes, \u003cstrong data-end=\"8097\" data-start=\"8086\"\u003ehepatic\u003c\/strong\u003e profile, \u003cstrong data-end=\"8129\" data-start=\"8107\"\u003eendocrine recovery\u003c\/strong\u003e, mood\/CNS effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8266\" data-start=\"8151\"\u003e\n\u003cp data-end=\"8266\" data-start=\"8153\"\u003e\u003cstrong data-end=\"8174\" data-start=\"8153\"\u003eOncology programs\u003c\/strong\u003e in \u003cstrong data-end=\"8203\" data-start=\"8178\"\u003eAR⁺\/ER⁺ breast cancer\u003c\/strong\u003e, rational \u003cstrong data-end=\"8263\" data-start=\"8214\"\u003ecombos (CDK4\/6 inhibitors, endocrine therapy)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8436\" data-start=\"8267\"\u003e\n\u003cp data-end=\"8436\" data-start=\"8269\"\u003e\u003cstrong data-end=\"8294\" data-start=\"8269\"\u003eRehab\/sarcopenia RCTs\u003c\/strong\u003e paired with \u003cstrong data-end=\"8342\" data-start=\"8307\"\u003eprogressive resistance training\u003c\/strong\u003e and \u003cstrong data-end=\"8366\" data-start=\"8347\"\u003eprotein targets\u003c\/strong\u003e; standardized functional endpoints (SPPB, stair-climb power, 6MWT).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8553\" data-start=\"8437\"\u003e\n\u003cp data-end=\"8553\" data-start=\"8439\"\u003e\u003cstrong data-end=\"8458\" data-start=\"8439\"\u003eDoping science:\u003c\/strong\u003e Comprehensive \u003cstrong data-end=\"8490\" data-start=\"8473\"\u003emetabolite ID\u003c\/strong\u003e, hair\/urine detection windows, and contamination risk mapping.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8558\" data-start=\"8555\"\u003e\n\u003ch3 data-end=\"8583\" data-start=\"8560\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9532\" data-start=\"8585\"\u003e\n\u003cli data-end=\"8729\" data-start=\"8585\"\u003e\n\u003cp data-end=\"8729\" data-start=\"8587\"\u003e\u003cstrong data-end=\"8657\" data-start=\"8587\"\u003eJournal of Pharmacology \u0026amp; Experimental Therapeutics; FASEB Journal\u003c\/strong\u003e — Anabolic and anti-catabolic signaling of RAD-class SARMs in muscle.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8851\" data-start=\"8730\"\u003e\n\u003cp data-end=\"8851\" data-start=\"8732\"\u003e\u003cstrong data-end=\"8778\" data-start=\"8732\"\u003eJournal of Bone and Mineral Research; Bone\u003c\/strong\u003e — SARM effects on BMD and biomechanical strength in osteopenic models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8963\" data-start=\"8852\"\u003e\n\u003cp data-end=\"8963\" data-start=\"8854\"\u003e\u003cstrong data-end=\"8895\" data-start=\"8854\"\u003eNeurobiology of Aging; Brain Research\u003c\/strong\u003e — AR-mediated neuroprotection and synaptic support (preclinical).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9063\" data-start=\"8964\"\u003e\n\u003cp data-end=\"9063\" data-start=\"8966\"\u003e\u003cstrong data-end=\"9005\" data-start=\"8966\"\u003eCancer Research; Annals of Oncology\u003c\/strong\u003e — Selective AR agonism in ER⁺\/AR⁺ breast cancer models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9182\" data-start=\"9064\"\u003e\n\u003cp data-end=\"9182\" data-start=\"9066\"\u003e\u003cstrong data-end=\"9128\" data-start=\"9066\"\u003eMedicine \u0026amp; Science in Sports \u0026amp; Exercise; AJP–Endocrinology\u003c\/strong\u003e — Strength\/function correlates under AR activation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9287\" data-start=\"9183\"\u003e\n\u003cp data-end=\"9287\" data-start=\"9185\"\u003e\u003cstrong data-end=\"9212\" data-start=\"9185\"\u003eDrug Testing \u0026amp; Analysis\u003c\/strong\u003e — Identification of RAD-140 long-term metabolites and detection windows.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9434\" data-start=\"9288\"\u003e\n\u003cp data-end=\"9434\" data-start=\"9290\"\u003e\u003cstrong data-end=\"9342\" data-start=\"9290\"\u003eHepatology Communications; J Clin Transl Hepatol\u003c\/strong\u003e — Case reports of liver injury associated with unregulated SARM products (class context).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9532\" data-start=\"9435\"\u003e\n\u003cp data-end=\"9532\" data-start=\"9437\"\u003e\u003cstrong data-end=\"9477\" data-start=\"9437\"\u003eClinical Pharmacology \u0026amp; Therapeutics\u003c\/strong\u003e — Oral PK\/PD considerations for non-steroidal SARMs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684862062930,"sku":"10","price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Rad140_injectable.png?v=1770834915","url":"https:\/\/sciencepeptideslab.com\/products\/injectable-s23-400mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}